BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
Federal Trade Commission

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208159

« Back to Dashboard

NDA 208159 describes VISTOGARD, which is a drug marketed by Wellstat Therap and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the VISTOGARD profile page.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.
Summary for 208159
Applicant:Wellstat Therap
Ingredient:uridine triacetate
Formulation / Manufacturing:see details
Pharmacology for NDA: 208159
Suppliers and Packaging for NDA: 208159
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VISTOGARD uridine triacetate GRANULE;ORAL 208159 NDA Wellstat Therapeutics Corporation 69468-151 69468-151-04 4 PACKET in 1 CARTON (69468-151-04) > 10 g in 1 PACKET (69468-151-10)
VISTOGARD uridine triacetate GRANULE;ORAL 208159 NDA Wellstat Therapeutics Corporation 69468-151 69468-151-10 10 g in 1 PACKET (69468-151-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength10GM/PACKET
Approval Date:Dec 11, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 4, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Dec 11, 2018
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Dec 11, 2022
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Argus Health
Federal Trade Commission
US Army
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.